Difference between revisions of "Edoxaban (Savaysa)"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 26: | Line 26: | ||
[[Category:Direct oral anticoagulants]] | [[Category:Direct oral anticoagulants]] | ||
[[Category:Factor Xa inhibitors]] | [[Category:Factor Xa inhibitors]] | ||
| + | |||
| + | [[Category:Venous thromboembolism (VTE) medications]] | ||
[[Category:Drugs FDA approved in 2015]] | [[Category:Drugs FDA approved in 2015]] | ||
Revision as of 02:28, 8 June 2018
General information
Class/mechanism: Factor Xa inhibitor, acts at the active site of factor Xa to inhibit its actions in the coagulation cascade.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
- 1/8/2015: FDA approved
- "for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant."
- "To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF)."
Also known as
- Code name: DU-176b
- Brand name: Savaysa